The rising cost of prescription drugs in the United States (U.S.) has become a significant concern for policymakers and patients. The U.S. often pays more for the same medications when compared to other developed nations, leading to proposals aimed at lowering these costs. One concept under consideration is the “Most Favored Nation” (MFN) pricing model for pharmaceuticals.
